

# Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022

<https://marketpublishers.com/r/PB44E23F109EN.html>

Date: June 2012

Pages: 185

Price: US\$ 2,635.00 (Single User License)

ID: PB44E23F109EN

## Abstracts

### Report Details

#### **Antibacterial medicines - discover performance and commercial prospects of companies**

How are leading companies in the antibacterial drugs market performing? Visiongain's new report gives you data, analyses and revenue predictions for antibacterial manufacturers.

See how top companies worldwide are performing and where they are heading. You assess their technologies, products and commercial prospects to 2022.

In our study you find analytical profiles for leading antibiotics producers. The work shows product ranges, R&D and sales prospects, with revenue forecasts from 2012 to 2022:

Pfizer

GSK

Merck & Co.

Novartis

Bayer

J&J

Cubist Pharmaceuticals

AstraZeneca

Abbott Laboratories

Medicis

Coverage of 10 other leading manufacturers and four top emerging companies.

You see how antibacterial drug producers compare, discovering how they can compete from 2012. You also find out what will stimulate and restrain business for companies.

The report covers leading pharmaceutical players, specialty companies and emerging organisations. Also, you find companies grouped by region of origin:

The US

Europe

Japan.

Our investigation gives you business research and analysis, including revenue forecasts at world market, submarket and company level to 2022. You find commercial data, predictions, and analyses for leading organisations, their industry and their market area.

### **Antibacterial drug producers: commercial outlook from 2012**

Where is the antibiotics market heading? Many opportunities exist in that industry and market, particularly with the development of new classes of antibacterial drug. In particular, treatments targeting C. difficile and MRSA infections will make a difference to 2022.

Patent expiries will challenge antibiotic manufacturers throughout this decade, with generic pharmaceutical sales prominent and growing. Companies will use product

lifecycle management to reduce declines of brands and stimulate their sales, our analysis shows.

What about product launches, new drug classes and expanded indications? The antibacterial R&D pipeline has limitations but holds promise. You find out how leading companies can contribute to our predicted growth and renewal of the market to 2022.

In 2012, more than 50 product candidates are in clinical trials. There are many opportunities for collaborations and in-licensing. Many under-met treatment needs exist.

Which companies are best placed to harness opportunities in the discovery, development, manufacturing and marketing of antibacterial medicines? Our study shows you and explains.

### **Company analyses, revenue forecasts, R&D and discussions of industry prospects**

In visiongain's report you find historical revenues, sales predictions, growth rates and market breakdowns. Also, you see discussions of companies, product portfolios, R&D, commercial news and revenue potentials. You receive 95 tables and 66 charts.

### **Ten ways Top 20 Antibacterial Drug Manufacturers 2012-2022 helps you**

In particular, our study gives you the following knowledge on the topic:

Assess 20 leading antibacterial drug manufacturers, discovering their activities and outlooks from 2012

Discover overall world market and submarket revenue forecasts to 2022

Receive analyses of leading companies, seeing revenue forecasts to 2022

View a comparative analysis of trends among antibacterial manufacturers

Find existing revenues and operational data for leading companies

Review pipeline developments, assessing R&D trends and potential

Analyse recent licensing deals and acquisitions

Investigate competition and opportunities influencing sales

Review prospects for emerging companies and antimicrobial specialists

Find out what will stimulate and restrain the industry and market from 2012.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

**Gain research and analysis on antibacterial drug producers now**

Our study is for everybody needing industry and market analyses of antibacterial drug developers and manufacturers. You find data, trends and predictions there. Please order that report now.

## Contents

### **1. EXECUTIVE SUMMARY**

- 1.1 Leading Antibacterial Drug Manufacturers: Overview of Findings
- 1.2 Chapter Breakdown
- 1.3 Research and Analysis Methods
- 1.4 Scope of this Report
  - 1.4.1 Drugs Considered for this Report
    - 1.4.1.1 Ophthalmic and Dermatologic Antibacterials
  - 1.4.2 The Chinese Antibacterial Drugs Market
- 1.5 Terminology Used in this Report

### **2. AN INTRODUCTION TO THE ANTIBACTERIAL DRUGS MARKET**

- 2.1 Bacterial Infections and Antibacterial Drugs
  - 2.1.1 Gram-Positive and Gram-Negative Infections
  - 2.1.2 Treating Bacterial Infections
- 2.2 The Antibacterial Drugs Market 2011
  - 2.2.1 Leading Classes of Antibacterial Drug
    - 2.2.1.1 Cephalosporins
    - 2.2.1.2 Penicillins
    - 2.2.1.3 Fluoroquinolones
    - 2.2.1.4 Macrolides
    - 2.2.1.5 Carbapenems
- 2.3 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022
  - 2.3.1 Market Drivers 2012-2022
  - 2.3.2 Market Restraints 2012-2022
- 2.4 Leading Antibacterial Drug Manufacturers in 2011
  - 2.4.1 Company Comparison
    - 2.4.1.1 Broad Product Portfolios
    - 2.4.1.2 Regional Focus
    - 2.4.1.3 Future of the Antibacterial Drugs Industry

### **3. THE LEADING US BIG PHARMA ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022**

- 3.1 Pfizer
  - 3.1.1 A Long History in Antibacterials

- 3.1.2 Antibacterial Product Portfolio
  - 3.1.2.1 Dalacin (Clindamycin)
  - 3.1.2.2 Sulperazon (Cefoperazone/Sulbactam)
  - 3.1.2.3 Tygacil (Tigecycline)
  - 3.1.2.4 Unasyn (Ampicillin/Sulbactam)
  - 3.1.2.5 Zithromax (Azithromycin)
  - 3.1.2.6 Zosyn (Piperacillin/Tazobactam)
  - 3.1.2.7 Zyvox (Linezolid)
- 3.1.3 Antibacterial Revenue 2011
- 3.1.4 Pipeline
  - 3.1.4.1 Pipeline 2007-2010
  - 3.1.4.2 PNU-100480 (Sutezolid)
- 3.1.5 Pfizer Antibacterials: SWOT Analysis
- 3.1.6 Antibacterial Revenue Forecast 2012-2022
- 3.2 Merck & Co.
  - 3.2.1 Antibacterial Product Portfolio
    - 3.2.1.1 Avelox (Moxifloxacin)
    - 3.2.1.2 Invanz (Ertapenem)
    - 3.2.1.3 Primaxin (Imipenem/Cilastatin)
  - 3.2.2 Antibacterial Revenue 2011
  - 3.2.3 Recent Licensing Deals
  - 3.2.4 Pipeline
    - 3.2.4.1 MK-3415A
    - 3.2.4.2 MK-7655
  - 3.2.5 Merck Antibacterials: SWOT Analysis
  - 3.2.6 Antibacterial Revenue Forecast 2012-2022
- 3.3 J&J
  - 3.3.1 Antibacterial Product Portfolio
    - 3.3.1.1 Doribax (Doripenem)
    - 3.3.1.2 Levaquin (Levofloxacin)
  - 3.3.2 Antibacterial Revenue 2011
    - 3.3.2.1 Patent Challenges
  - 3.3.3 Decreasing Investment in Antibacterials
  - 3.3.4 Pipeline: TMC207
  - 3.3.5 J&J Antibacterials: SWOT Analysis
  - 3.3.6 Antibacterial Revenue Forecast 2012-2022
- 3.4 Abbott Laboratories
  - 3.4.1 Antibacterial Product Portfolio
    - 3.4.1.1 Biaxin (Clarithromycin)

- 3.4.2 Antibacterial Revenue 2011
- 3.4.3 Abbott Antibacterials: SWOT Analysis
- 3.4.4 Antibacterial Revenue Forecast 2012-2022

## **4. THE LEADING EUROPEAN BIG PHARMA ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022**

### **4.1 GSK**

- 4.1.1 Antibacterial Product Portfolio
  - 4.1.1.1 Augmentin (Amoxicillin/Clavulanate)
  - 4.1.1.2 Bactroban (Mupirocin)
  - 4.1.1.3 Duac (Clindamycin/Benzoyl Peroxide)
  - 4.1.1.4 Fortum (Ceftazidime)
  - 4.1.1.5 Zinnat (Cefuroxime)
- 4.1.2 Antibacterial Revenue 2011
- 4.1.3 Antibacterials in the US
- 4.1.4 Pipeline
  - 4.1.4.1 GSK2251052
  - 4.1.4.2 GSK1322322
- 4.1.5 GSK Antibacterials: SWOT Analysis
- 4.1.6 Antibacterial Revenue Forecast 2012-2022

### **4.2 Novartis**

- 4.2.1 Antibacterial Product Portfolio
  - 4.2.1.1 Ciprodex (Ciprofloxacin/Dexamethasone)
  - 4.2.1.2 Cubicin (Daptomycin)
  - 4.2.1.3 Moxeza (Moxifloxacin)
  - 4.2.1.4 TOBI Podhaler (Tobramycin Inhalation Powder)
  - 4.2.1.5 Vigamox (Moxifloxacin)
- 4.2.2 Antibacterial Revenue 2011
- 4.2.3 Entering and Exiting Licensing Agreements
- 4.2.4 Pipeline
  - 4.2.4.1 Finafloxacin
  - 4.2.4.2 LFF571
- 4.2.5 Novartis Antibacterials: SWOT Analysis
- 4.2.6 Antibacterial Revenue Forecast 2012-2022

### **4.3 Bayer**

- 4.3.1 Antibacterial Product Portfolio
  - 4.3.1.1 Avelox (Moxifloxacin)
  - 4.3.1.2 Cipro (Ciprofloxacin)

- 4.3.2 Antibacterial Revenue 2011
- 4.3.3 Avelox Patent Challenges
- 4.3.4 Bayer and Trius Therapeutics
- 4.3.5 Pipeline
  - 4.3.5.1 Ciprofloxacin Inhale
  - 4.3.5.2 Amikacin Inhale
- 4.3.6 Bayer Antibacterials: SWOT Analysis
- 4.3.7 Antibacterial Revenue Forecast 2012-2022
- 4.4 AstraZeneca
  - 4.4.1 Antibacterial Product Portfolio
    - 4.4.1.1 Cubicin (Daptomycin)
    - 4.4.1.2 Merrem (Meropenem)
    - 4.4.1.3 Zinforo (Ceftaroline)
  - 4.4.2 Antibacterial Revenue 2011
  - 4.4.3 AstraZeneca Acquires Novexel
  - 4.4.4 Pipeline
    - 4.4.4.1 CAZ-AVI
    - 4.4.4.2 CEF104
    - 4.4.4.3 NXL103
    - 4.4.4.4 AZD5847
  - 4.4.5 AstraZeneca Antibacterials: SWOT Analysis
  - 4.4.6 Antibacterial Revenue Forecast 2012-2022
- 4.5 Roche
  - 4.5.1 Antibacterial Product Portfolio
    - 4.5.1.1 Rocephin (Ceftriaxone)
  - 4.5.2 Antibacterial Revenue 2011
  - 4.5.3 Roche Antibacterials: SWOT Analysis
  - 4.5.4 Antibacterial Revenue Forecast 2012-2022

## **5. THE LEADING JAPANESE ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022**

- 5.1 Daiichi Sankyo
  - 5.1.1 Antibacterial Product Portfolio
    - 5.1.1.1 Cravit (Levofloxacin)
  - 5.1.2 Antibacterial Revenue 2011
  - 5.1.3 Lifecycle Management
  - 5.1.4 Pipeline
  - 5.1.5 Daiichi Sankyo Antibacterials: SWOT Analysis



- 5.1.6 Antibacterial Revenue Forecast 2012-2022
- 5.2 Shionogi & Co
  - 5.2.1 Antibacterial Product Portfolio
    - 5.2.1.1 Finibax (Doripenem)
    - 5.2.1.2 Flomox (Cefcapene)
    - 5.2.1.3 Shionogi Acquires Victory Pharma's Portfolio
  - 5.2.2 Antibacterial Revenue 2011
  - 5.2.3 Lifecycle Management
  - 5.2.4 Patent Challenges
  - 5.2.5 Pipeline
    - 5.2.5.1 S-649266
  - 5.2.6 Shionogi Antibacterials: SWOT Analysis
  - 5.2.7 Antibacterial Revenue Forecast 2012-2022
- 5.3 Meiji Seika Pharma
  - 5.3.1 Antibacterial Product Portfolio
    - 5.3.1.1 Meiact (Cefditoren)
  - 5.3.2 Antibacterial Revenue 2011
  - 5.3.3 Generic Competition
  - 5.3.4 ME1071
  - 5.3.5 Meiji Seika Pharma Antibacterials: SWOT Analysis
  - 5.3.6 Antibacterial Revenue Forecast 2012-2022
- 5.4 Astellas Pharma
  - 5.4.1 Antibacterial Product Portfolio
    - 5.4.1.1 Cefzon (Cefdinir)
    - 5.4.1.2 Geninax (Garenoxacin)
  - 5.4.2 Antibacterial Revenue 2011
  - 5.4.3 Astellas and Optimer Pharmaceuticals
  - 5.4.4 Astellas and Theravance
  - 5.4.5 Astellas Pharma Antibacterials: SWOT Analysis
  - 5.4.6 Antibacterial Revenue Forecast 2012-2022
- 5.5 Dainippon Sumitomo Pharma
  - 5.5.1 Meropen (Meropenem)
  - 5.5.2 Antibacterial Revenue 2011
  - 5.5.3 Licensing Deals
  - 5.5.4 Pipeline
    - 5.5.4.1 DSP-5990
  - 5.5.5 Dainippon Sumitomo Antibacterials: SWOT Analysis
  - 5.5.6 Antibacterial Revenue Forecast 2012-2022

## **6. THE LEADING SPECIALIST ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022**

### **6.1 Cubist Pharmaceuticals**

#### **6.1.1 Antibacterial Product Portfolio**

##### **6.1.1.1 Cubicin (Daptomycin)**

#### **6.1.2 Antibacterial Revenue 2011**

#### **6.1.3 Lifecycle Management**

#### **6.1.4 Patent Challenges**

#### **6.1.5 Pipeline**

##### **6.1.5.1 CXA-201**

##### **6.1.5.2 CB-315**

#### **6.1.6 Cubist Antibacterials: SWOT Analysis**

#### **6.1.7 Antibacterial Revenue Forecast 2012-2022**

### **6.2 Medicis**

#### **6.2.1 Antibacterial Product Portfolio**

##### **6.2.1.1 Solodyn (Minocycline)**

##### **6.2.1.2 Ziana (Clindamycin/Tretinoin)**

#### **6.2.2 Antibacterial Revenue 2011**

#### **6.2.3 Patent Extensions and Challenges**

#### **6.2.4 Pipeline**

##### **6.2.4.1 GW05**

#### **6.2.5 Medicis Antibacterials: SWOT Analysis**

#### **6.2.6 Antibacterial Revenue Forecast 2012-2022**

### **6.3 Salix Pharmaceuticals**

#### **6.3.1 Xifaxan (Rifaximin)**

#### **6.3.2 Antibacterial Revenue 2011**

#### **6.3.3 Expanding Approved Indications**

#### **6.3.4 Salix Pharmaceuticals Antibacterials: SWOT Analysis**

#### **6.3.5 Antibacterial Revenue Forecast 2012-2022**

### **6.4 ViroPharma**

#### **6.4.1 Vancocin (Vancomycin)**

#### **6.4.2 Antibacterial Revenue 2011**

#### **6.4.3 Generic Competition**

#### **6.4.4 Pipeline: VP20621**

#### **6.4.5 ViroPharma Antibacterials: SWOT Analysis**

#### **6.4.6 Antibacterial Revenue Forecast 2012-2022**

### **6.5 Warner Chilcott**

#### **6.5.1 Doryx (Doxycycline)**

6.5.2 Antibacterial Revenue 2011

6.5.3 Patent Challenges

6.5.4 Pipeline

6.5.5 Warner Chilcott Antibacterials: SWOT Analysis

6.5.6 Antibacterial Revenue Forecast 2012-2022

## 6.6 Allergan

6.6.1 Antibacterial Product Portfolio

6.6.1.1 Zymar (Gatifloxacin)

6.6.1.2 Zymaxid (Gatifloxacin)

6.6.2 Antibacterial Revenue 2011

6.6.3 Patent Challenges

6.6.4 Allergan Antibacterials: SWOT Analysis

6.6.5 Antibacterial Revenue Forecast 2012-2022

## 7. EMERGING ANTIBACTERIAL MANUFACTURERS

7.1 Pipeline Companies 2012

7.2 Durata Therapeutics

7.2.1 Future Outlook

7.3 Optimer Pharmaceuticals

7.3.1 Future Outlook

7.4 Rib-X Pharmaceuticals

7.4.1 Future Outlook

7.5 Trius Therapeutics

7.5.1 Future Outlook

## 8. CONCLUSIONS

8.1 Big Pharma Dominated the Antibacterials Market in 2011

8.2 The Rise of Generics

8.3 Small Companies Can Have a Big Impact on the Industry and Market to 2022

## List Of Tables

### LIST OF TABLES

Table 1.1	Currency Exchange Rates, 2011
Table 1.2	Common Abbreviations Used in this Report
Table 2.1	Classification of Common Infection-Causing Bacteria
Table 2.2	Antibacterial Drugs Market by Class, 2010-2011
Table 2.3	Selected Classes of Antibacterial Drug and their Mechanism of Action
Table 2.4	Cephalosporins: Role in the Antibacterial Drugs Market, 2011
Table 2.5	Penicillins: Role in the Antibacterial Drugs Market, 2011
Table 2.6	Fluoroquinolones: Role in the Antibacterial Drugs Market, 2011
Table 2.7	Macrolides: Role in the Antibacterial Drugs Market, 2011
Table 2.8	Carbapenems: Role in the Antibacterial Drugs Market, 2011
Table 2.9	Antibacterial Drugs: Overall World Market and Submarket Forecasting, 2011, 2016 & 2022
Table 2.10	Top 20 Antibacterial Manufacturers by Revenue, 2011
Table 2.11	Antibacterial Revenue as a Share of Pharmaceutical Revenue, 2011
Table 3.1	Pfizer: Key Facts, 2012
Table 3.2	Pfizer: Antibacterial Revenue, 2009-2011
Table 3.3	Pfizer: Antibacterial SWOT Analysis, 2012-2022
Table 3.4	Pfizer: Antibacterial Revenue Forecast, 2011-2022
Table 3.5	Merck & Co: Key Facts, 2012
Table 3.6	Merck & Co: Antibacterial Revenue, 2009-2011
Table 3.7	Merck & Co: Antibacterial SWOT Analysis, 2012-2022
Table 3.8	Merck & Co: Antibacterial Revenue Forecast, 2011-2022
Table 3.9	J&J: Key Facts, 2012
Table 3.10	J&J: Antibacterial Revenue, 2009-2011
Table 3.11	J&J: Antibacterial SWOT Analysis, 2012-2022
Table 3.12	J&J: Antibacterial Revenue Forecast, 2011-2022
Table 3.13	Abbott: Key Facts, 2012
Table 3.14	Abbott: Antibacterial SWOT Analysis, 2012-2022
Table 3.15	Abbott: Antibacterial Revenue Forecast, 2011-2022
Table 4.1	GSK: Key Facts, 2012
Table 4.2	GSK: Antibacterial Revenue, 2010-2011
Table 4.3	Augmentin, Revenue by Region, 2011
Table 4.4	GSK: Antibacterial Drug Pipeline, 2012
Table 4.5	GSK: Antibacterial SWOT Analysis, 2012-2022
Table 4.6	GSK: Antibacterial Revenue Forecast, 2011-2022

Table 4.7 Novartis: Key Facts, 2012
Table 4.8 Novartis: Antibacterial Revenue, 2009-2011
Table 4.9 Novartis: Antibacterial SWOT Analysis, 2012-2022
Table 4.10 Novartis: Antibacterial Revenue Forecast, 2011-2022
Table 4.11 Bayer: Key Facts, 2012
Table 4.12 Bayer: Antibacterial Revenue, 2009-2011
Table 4.13 Avelox: Patent Expiries by Country, 2013-2015
Table 4.14 Bayer: Antibacterial SWOT Analysis, 2012-2022
Table 4.15 Bayer: Antibacterial Revenue Forecast, 2011-2022
Table 4.16 AstraZeneca: Key Facts, 2012
Table 4.17 AstraZeneca: Antibacterial Revenue, 2008-2011
Table 4.18 AstraZeneca: Antibacterial SWOT Analysis, 2012-2022
Table 4.19 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022
Table 4.20 Roche: Key Facts, 2012
Table 4.21 Roche: Antibacterial Revenue, Q1-Q4 2011
Table 4.22 Roche: Antibacterial Revenue by Region, Q1 2012
Table 4.23 Roche: Antibacterial SWOT Analysis, 2012-2022
Table 4.24 Roche: Antibacterial Revenue Forecast, 2011-2022
Table 5.1 Daiichi Sankyo: Key Facts, 2012
Table 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011
Table 5.3 Daiichi Sankyo: Antibacterial SWOT Analysis, 2012-2022
Table 5.4 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022
Table 5.5 Shionogi: Key Facts, 2012
Table 5.6 Shionogi: Antibacterial SWOT Analysis, 2012-2022
Table 5.7 Shionogi: Antibacterial Revenue Forecast, 2011-2022
Table 5.8 Meiji Seika Pharma: Key Facts, 2012
Table 5.9 Meiji Seika Pharma: Antibacterial SWOT Analysis, 2012-2022
Table 5.10 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022
Table 5.11 Astellas Pharma: Key Facts, 2012
Table 5.12 Astellas Pharma: Leading Antibacterial Drug Revenue, FY 2007-2011
Table 5.13 Astellas Pharma: Antibacterial SWOT Analysis, 2012-2022
Table 5.14 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022
Table 5.15 Daiippon Sumitomo: Key Facts, 2012
Table 5.16 Daiippon Sumitomo: Antibacterial Revenue, FY 2009-2011
Table 5.17 Daiippon Sumitomo: Antibacterial SWOT Analysis, 2012-2022
Table 5.18 Daiippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022
Table 6.1 Cubist Pharmaceuticals: Key Facts, 2012
Table 6.2 Cubist: Antibacterial Revenue, 2008-2011
Table 6.3 Cubicin: International Revenue Payments, 2008-2011

Table 6.4 Cubist: Antibacterial SWOT Analysis, 2012-2022
Table 6.5 Cubist: Antibacterial Revenue Forecast, 2011-2022
Table 6.6 Medicis: Key Facts, 2012
Table 6.7 Medicis: Antibacterial Revenue, 2009-2011
Table 6.8 Medicis: Antibacterial SWOT Analysis, 2012-2022
Table 6.9 Medicis: Antibacterial Revenue Forecast, 2011-2022
Table 6.10 Salix Pharmaceuticals: Key Facts, 2012
Table 6.11 Salix: Antibacterial Revenue, 2009-2011
Table 6.12 Salix: Antibacterial SWOT Analysis, 2012-2022
Table 6.13 Salix: Antibacterial Revenue Forecast, 2011-2022
Table 6.14 ViroPharma: Key Facts, 2012
Table 6.15 ViroPharma: Antibacterial Revenue, 2009-2011
Table 6.16 ViroPharma: Antibacterial SWOT Analysis, 2012-2022
Table 6.17 ViroPharma: Antibacterial Revenue Forecast, 2011-2022
Table 6.18 Warner Chilcott: Key Facts, 2012
Table 6.19 Warner Chilcott: Antibacterial SWOT Analysis, 2012-2022
Table 6.20 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022
Table 6.21 Allergan: Key Facts, 2012
Table 6.22 Allergan: Antibacterial SWOT Analysis, 2012-2022
Table 6.23 Allergan: Antibacterial Revenue Forecast, 2011-2022
Table 7.1 Emerging Companies in the Antibacterial Drugs Market, 2012
Table 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011

## List Of Figures

### LIST OF FIGURES

- Figure 2.1 Antibacterial Drugs Market by Class, 2010-2011
- Figure 2.2 Antibacterial Drugs: Overall Market Forecast, 2011, 2016 & 2022
- Figure 2.3 Antibacterial Drugs Market: Drivers and Restraints, 2012-2022
- Figure 2.4 Top 20 Antibacterial Manufacturers by Revenue, 2011
- Figure 2.5 Antibacterial Drug Market Entry, 1935-2004
- Figure 3.1 Pfizer: Antibacterial Market History, 1944-2009
- Figure 3.2 Pfizer: Antibacterial Revenue Shares, 2011
- Figure 3.3 Pfizer: Antibacterial Revenue Forecast, 2011-2022
- Figure 3.4 Pfizer: Antibacterial Market Share, 2011-2022
- Figure 3.5 Merck & Co: Antibacterial Revenue, 2009-2011
- Figure 3.6 Merck & Co: Antibacterial Revenue Forecast, 2011-2022
- Figure 3.7 Merck & Co: Antibacterial Market Share, 2011-2022
- Figure 3.8 J&J: Antibacterial Revenue, 2009-2011
- Figure 3.9 J&J: Antibacterial Revenue Forecast, 2011-2022
- Figure 3.10 J&J: Antibacterial Market Share, 2011-2022
- Figure 3.11 Abbott: Antibacterial Revenue Forecast, 2011-2022
- Figure 3.12 Abbott: Antibacterial Market Share, 2011-2022
- Figure 4.1 GSK: Antibacterial Revenue Shares, 2011
- Figure 4.2 Augmentin, Revenue Shares by Region, 2011
- Figure 4.3 GSK: Antibacterial Revenue Forecast, 2011-2022
- Figure 4.4 GSK: Antibacterial Market Share, 2011-2022
- Figure 4.5 Novartis: Antibacterial Revenue Shares, 2011
- Figure 4.6 Novartis: Antibacterial Revenue Forecast, 2011-2022
- Figure 4.7 Novartis: Antibacterial Market Share, 2011-2022
- Figure 4.8 Bayer: Antibacterial Revenue, 2009-2011
- Figure 4.9 Bayer: Antibacterial Revenue Forecast, 2011-2022
- Figure 4.10 Bayer: Antibacterial Market Share, 2011-2022
- Figure 4.11 AstraZeneca: Antibacterial Sales Revenue, 2008-2011
- Figure 4.12 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022
- Figure 4.13 AstraZeneca: Antibacterial Market Share, 2011-2022
- Figure 4.14 Roche: Antibacterial Revenue Shares, Q1-Q4 2011
- Figure 4.15 Roche: Antibacterial Revenue Shares by Region, Q1 2012
- Figure 4.16 Roche: Antibacterial Revenue Forecast, 2011-2022
- Figure 4.17 Roche: Antibacterial Market Share, 2011-2022
- Figure 5.1 Daiichi Sankyo: Antibacterial Market History, 1937-1993



Figure 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011  
Figure 5.3 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022  
Figure 5.4 Daiichi Sankyo: Antibacterial Market Share, 2011-2022  
Figure 5.5 Shionogi: Antibacterial Revenue Forecast, 2011-2022  
Figure 5.6 Shionogi: Antibacterial Market Share, 2011-2022  
Figure 5.7 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022  
Figure 5.8 Meiji Seika Pharma: Antibacterial Market Share, 2011-2022  
Figure 5.9 Astellas Pharma: Leading Antibacterial Drug Revenues, FY 2007-2011  
Figure 5.10 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022  
Figure 5.11 Astellas Pharma: Antibacterial Market Share, 2011-2022  
Figure 5.12 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011  
Figure 5.13 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022  
Figure 5.14 Dainippon Sumitomo: Antibacterial Market Share, 2011-2022  
Figure 6.1 Cubist: Antibacterial Revenue, 2008-2011  
Figure 6.2 Cubicin: International Revenue Payments, 2008-2011  
Figure 6.3 Cubist: Antibacterial Market Share, 2011-2022  
Figure 6.4 Cubist: Antibacterial Revenue Forecast, 2011-2022  
Figure 6.5 Medicis: Antibacterial Revenue, 2009-2011  
Figure 6.6 Medicis: Antibacterial Revenue Forecast, 2011-2022  
Figure 6.7 Medicis: Antibacterial Market Share, 2011-2022  
Figure 6.8 Salix: Antibacterial Revenue, 2009-2011  
Figure 6.9 Salix: Antibacterial Revenue Forecast, 2011-2022  
Figure 6.10 Salix: Antibacterial Market Share, 2011-2022  
Figure 6.11 ViroPharma: Antibacterial Revenue, 2009-2011  
Figure 6.12 ViroPharma: Antibacterial Revenue Forecast, 2011-2022  
Figure 6.13 ViroPharma: Antibacterial Market Share, 2011-2022  
Figure 6.14 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022  
Figure 6.15 Warner Chilcott: Antibacterial Market Share, 2011-2022  
Figure 6.16 Allergan: Antibacterial Revenue Forecast, 2011-2022  
Figure 6.17 Allergan: Antibacterial Market Share, 2011-2022  
Figure 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011

## **COMPANIES LISTED**

Abbott Laboratories  
Adolor (part of Cubist)  
Advanced Life Sciences  
AiCuris  
Akorn



Alcon Laboratories (a division of Novartis)  
Alfa Wassermann  
Allergan  
Anacor Pharmaceuticals  
Apotex  
Astellas Pharma  
AstraZeneca  
Barr Laboratories (part of Teva)  
Basilea Pharmaceutica  
Bayer  
BioRelix  
Biovail Laboratories (part of Valeant Pharmaceuticals)  
Bristol-Myers Squibb  
Calixa Therapeutics (part of Cubist)  
Cempra Pharmaceuticals  
Chiron (now part of Novartis)  
Cornerstone Therapeutics  
Cubist Pharmaceuticals  
Daiichi Sankyo  
Daiichi Sankyo Pharmaceutical (Beijing)  
Daiichi Sankyo Pharmaceutical (Shanghai)  
Dainippon Pharmaceutical (part of Dainippon Sumitomo)  
Dainippon Sumitomo Pharma  
DAVA Pharmaceuticals  
Department of Health and Human Services' Biomedical Advanced Research and  
Development Authority (BARDA) [US]  
Dr Reddy's Laboratories  
Durata Therapeutics  
Eli Lilly  
EMA Committee for Medicinal Products for Human Use (CHMP) [EU]  
European Medicines Agency (EMA)  
Food and Drug Administration (FDA) [US]  
Forest Laboratories  
Fujisawa Pharmaceutical (part of Astellas Pharma)  
Furiex Pharmaceuticals  
Genzyme (part of Sanofi)  
Graceway Pharmaceuticals  
GSK  
Heritage Pharmaceuticals

Hikma Farmaceutica  
Hi-Tech Pharmacal  
Hospira  
Impax Laboratories  
Innovative Medicines Initiative [EU]  
Itochu Chemical Frontier  
Janssen Pharmaceutica (a subsidiary of J&J)  
Japan Patent Office (JPO)  
Johnson & Johnson (J&J)  
Kyorin Pharmaceutical  
Lupin  
Massachusetts Biologic Laboratories  
Mayne Pharma  
Medarex (part of Bristol-Myers Squibb)  
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]  
Medicis  
Medison Pharma  
Meiji Holdings (parent company of Meiji Seika Pharma)  
Meiji Seika Pharma  
Merck & Co.  
MerLion Pharmaceuticals  
Ministry of Health, Labor and Welfare (MHLW)  
Mylan  
Mylan Seiyaku (a subsidiary of Mylan)  
Nabriva Therapeutics  
Nanotherapeutics  
National Institute of Allergy and Infectious Diseases (NIAID) [US]  
Nektar Therapeutics  
Nestl?  
NeuTec Pharma (part of Novartis, now closed)  
Nichi-Iko Pharmaceutical  
Nipro Pharma  
Novartis  
Novexel (part of AstraZeneca)  
Optimer Biotechnology (a subsidiary of Optimer)  
Optimer Pharmaceuticals  
Ortho-McNeil Pharmaceutical (a subsidiary of J&J)  
Paratek Pharmaceuticals  
Patent and Trademark Office [US]

Peninsula Pharmaceuticals (part of J&J)  
Pfizer  
Pharmaceutical Research and Manufacturers of America (PhRMA)  
Pharmacia (part of Pfizer)  
Pliva (part of Teva)  
Proctor & Gamble (P&G)  
Protez Pharmaceuticals (part of Novartis, now closed)  
Ranbaxy (part of Daiichi Sankyo)  
Rib-X Pharmaceuticals  
Roche  
Rutgers University [US]  
Salix Pharmaceuticals  
Sandoz (a division of Novartis)  
Sanofi  
Sawai Pharmaceutical  
Schering-Plough (part of Merck & Co)  
Scottish Medicines Consortium (SMC)  
Senju Pharmaceutical  
Sequella  
Shantou Meiji Pharmaceuticals (a subsidiary of Meiji Seika Pharma)  
Shionogi & Co  
Sincere Pharmaceutical Group  
State Food and Drug Administration (SFDA) [China]  
Stiefel Laboratories (part of GSK)  
Strides Arcolab  
Sumitomo Pharmaceutical (part of Dainippon Sumitomo)  
Sunovion Pharmaceuticals  
TaiGen Biotechnology  
Taisho Pharmaceutical  
Taiyo Yakuin (Taiyo Pharmaceutical Industry)  
Takeda Pharmaceutical  
TB Alliance  
Tedec-Meiji Farma (a subsidiary of Meiji Seika Pharma)  
Tetraphase Pharmaceuticals  
Teva Pharmaceutical Industries  
The Medicines Company  
Theravance  
Tibotec Pharmaceuticals (part of Janssen Pharmaceutica)  
Towa Pharmaceutical

Toyama Chemical  
Trius Therapeutics  
Upjohn (part of Pfizer)  
Victory Pharma  
Vicuron Pharmaceuticals (part of Durata)  
ViroPharma  
Wakunaga Pharmaceutical  
Warner Chilcott  
Warner Lambert (part of Pfizer)  
Watson Pharmaceuticals  
Women First HealthCare  
World Health Organization (WHO)  
Wyeth Pharmaceuticals (part of Pfizer)  
Yale University [US]  
Yamanouchi Pharmaceutical (part of Astellas)  
Zuellig Pharma

## I would like to order

Product name: Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022

Product link: <https://marketpublishers.com/r/PB44E23F109EN.html>

Price: US\$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB44E23F109EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970